Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Summit Therapeutics Inc.

SMMT · Nasdaq · CIK 0001599298 · Healthcare · Biotechnology

INSIDER SIGNAL

69.8 / 100

3 buyers · 6 purchase transaction lines · $103.6M gross purchase

WHY THIS SIGNAL?

Buyer breadthModerate
Purchase sizeStrong
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+21.0 / 35
Purchase size+24.6 / 25
Role+13.0 / 20
Recency+1.2 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: Co-Chief Executive Officer (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Zanganeh MahkamCo-Chief Executive Officer
●●
DUGGAN ROBERT WCo-Chief Executive Officer
●●
Soni Manmeet SinghCOO and CFO
●
Anand BhaskarChief Accounting Officer
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS3
PURCHASE CONCENTRATION50%Largest buyer: Zanganeh Mahkam · $51.4M
CLUSTER BUYING · 15D3 insidersPeak activity: 2026-06-04–2026-06-12

Roles in the peak window: COO and CFO, Co-Chief Executive Officer. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

69.8 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 69.9
  2. 69.9
  3. 69.9
  4. 69.8
  5. 69.8

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

9Purchases
0Sales
7Other Form 4 lines
11SEC filings · 365 days
BUYING6 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER1 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+3.5%
3M
+15.0%
6M
-10.6%
12M
-24.6%

Volatility & liquidity

Volatility
86.4%
Beta
—
Avg daily value
USD 103.9M

Valuation

Market cap
USD 14.0B
P/E
—

Fundamentals

Profit margin
—
ROE
-163.9%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-17 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
41,155,196
Previous report
41,081,179
Avg daily volume
8,495,750
Days to cover
4.8

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-12Zanganeh MahkamPurchase (P)Common Stock3,810,000USD 13.12USD 49,987,200SEC filing ↗
2026-06-12DUGGAN ROBERT WPurchase (P)Common Stock3,810,000USD 13.12USD 49,987,200SEC filing ↗
2026-06-04Zanganeh MahkamPurchase (P)Common Stock100,000USD 14.60USD 1,460,000SEC filing ↗
2026-06-04Soni Manmeet SinghPurchase (P)Common Stock50,000USD 14.45USD 722,250SEC filing ↗
2026-06-04DUGGAN ROBERT WPurchase (P)Common Stock100,000USD 14.60USD 1,460,000SEC filing ↗
2025-10-21Zanganeh MahkamPurchase (P)Common Stock26,680USD 18.74USD 499,983SEC filing ↗
2025-10-21Xia YuPurchase (P)Common Stock533,617USD 18.74USD 9,999,983SEC filing ↗
2025-10-21DUGGAN ROBERT WPurchase (P)Common Stock26,680USD 18.74USD 499,983SEC filing ↗
2025-09-11Zanganeh MahkamPurchase (P)Common Stock5,000USD 18.07USD 90,350SEC filing ↗
2025-09-11DUGGAN ROBERT WPurchase (P)Common Stock5,000USD 18.07USD 90,350SEC filing ↗
2025-09-10Zanganeh MahkamPurchase (P)Common Stock333,394USD 17.68USD 5,894,406SEC filing ↗
2025-09-10DUGGAN ROBERT WPurchase (P)Common Stock333,394USD 17.68USD 5,894,406SEC filing ↗
2024-03-27Zanganeh MahkamPurchase (P)Common Stock80,321USD 3.72USD 298,594SEC filing ↗
2024-03-26Zanganeh MahkamPurchase (P)Common Stock30,000USD 3.75USD 112,500SEC filing ↗
2024-03-26Dhingra AnkurPurchase (P)Common Stock100,000USD 3.75USD 375,000SEC filing ↗

Form 4 evidence

16 transaction lines in the latest 365-day window; 75 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-08Anand BhaskarAward / grant (A)Common Stock100,000USD 0.00USD 0SEC filing ↗
2026-06-12Zanganeh MahkamPurchase (P)Common Stock3,810,000USD 13.12USD 49,987,200SEC filing ↗
2026-06-12DUGGAN ROBERT WPurchase (P)Common Stock3,810,000USD 13.12USD 49,987,200SEC filing ↗
Show recent Form 4 evidence (13 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-08Anand BhaskarAward / grant (A)Common Stock100,000USD 0.00USD 0SEC filing ↗
2026-06-12Zanganeh MahkamPurchase (P)Common Stock3,810,000USD 13.12USD 49,987,200SEC filing ↗
2026-06-12DUGGAN ROBERT WPurchase (P)Common Stock3,810,000USD 13.12USD 49,987,200SEC filing ↗
2026-06-04Zanganeh MahkamPurchase (P)Common Stock100,000USD 14.60USD 1,460,000SEC filing ↗
2026-06-04Soni Manmeet SinghPurchase (P)Common Stock50,000USD 14.45USD 722,250SEC filing ↗
2026-06-04DUGGAN ROBERT WPurchase (P)Common Stock100,000USD 14.60USD 1,460,000SEC filing ↗
2025-10-21Zanganeh MahkamPurchase (P)Common Stock26,680USD 18.74USD 499,983SEC filing ↗
2025-10-21Zanganeh MahkamAward / grant (A)Common Stock14,247,597USD 18.74USD 266,999,968SEC filing ↗
2025-10-21Xia YuPurchase (P)Common Stock533,617USD 18.74USD 9,999,983SEC filing ↗
2025-10-21Soni Manmeet SinghAward / grant (A)Common Stock53,361USD 18.74USD 999,985SEC filing ↗
2025-10-21DUGGAN ROBERT WPurchase (P)Common Stock26,680USD 18.74USD 499,983SEC filing ↗
2025-10-21DUGGAN ROBERT WAward / grant (A)Common Stock14,247,597USD 18.74USD 266,999,968SEC filing ↗
2025-10-21Anand BhaskarAward / grant (A)Common Stock26,680USD 18.74USD 499,983SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerSMMT
CIK0001599298
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history75 transaction lines from 2020-11-06 to 2026-10-08
42 P purchase lines · 5 S sale lines · 28 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.